AskAt

AskAt is a Japanese bio-pharmaceutical venture company that spun out from RaQualia Pharma Inc. in 2013, with roots tracing back to Pfizer Global Research and Development. The company focuses on discovering and developing new drugs, with a portfolio of compounds aimed at treating cancer, pain, dementia, and autoimmune diseases. Many of these compounds are positioned to be either "first-in-class" or "best-in-class" therapeutics. AskAt's business model is centered on an open, global collaboration network involving universities, research institutions, and other pharmaceutical companies to advance its pipeline programs. It generates revenue by licensing the intellectual property of its developed compounds to larger pharmaceutical companies.

The company's therapeutic approach includes developing EP4 antagonists to enhance cancer immunotherapy, creating safer and more effective COX-2 inhibitors as alternatives to opioids for chronic pain, and focusing on early intervention for dementia before the disease significantly progresses. The leadership team, including President Akihiro Furuta, brings decades of experience from major global pharmaceutical companies and was central to Pfizer's drug discovery research in Japan. Through its network and expertise, AskAt aims to efficiently deliver new medications to patients worldwide.

Keywords: bio-pharmaceutical, drug discovery, compound development, licensing, cancer immunotherapy, pain therapy, dementia treatment, autoimmune diseases, RaQualia Pharma, Pfizer spin-out, EP4 antagonist, COX-2 inhibitors, clinical candidates, pre-clinical candidates, global collaboration network, intellectual property licensing, novel therapeutics, Japanese biotech